Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the...
22 Januar 2021 - 07:00AM
Amsterdam, The Netherlands, January 22,
2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical-stage
biopharmaceutical company developing innovative NK-cell-based
medicines for the treatment of life-threatening diseases, today
announces that four abstracts related to its K-NK-cell therapy
platform were accepted for presentation at the TCT Meetings, the
Transplantation & Cellular Therapy Meetings of the American
Society of Transplantation and Cellular Therapy (ASTCT) and Center
for International Blood & Marrow Transplant Research (CIBMTR),
which is being held virtually from February 8–12, 2021.
The abstracts are now available at 2021 TCT |
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
(confex.com)
Details of the oral presentation are as
follows:
- Oral Presentation #80: Results of a Phase I
Study with Mb-IL21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients
with Refractory Acute Myeloid LeukemiaPresenter:
Stefan O. Ciurea, MDPresentation Date: Wednesday,
February 10, 2021: 4:45 PM – 5:00 PM CST
Details of the poster presentations are as follows:
- Poster #172: A Phase I Trial of Incorporating
Natural Killer (K-NK) Cells for Patients with Chronic Myeloid
Leukemia (CML)and Molecular Residual Disease after Tyrosine Kinase
Inhibitor (TKI) TherapyPresenter: Lindsay Rein,
MDAffiliation: Duke University Medical Center,
Durham, NC
- Poster #411: A Phase I Clinical Trial Testing
the Safety of IL-21-Expanded, Off-the-Shelf, Natural Killer Cells
for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic
SyndromePresenter: Sumithira Vasu,
MDAffiliation: The Ohio State University,
Columbus, OH
- Poster #531 - BMT CTN 1803: Haploidentical
Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse
in AML and MDS (NK-REALM)Presenter: Sumithira
VasuAffiliation: The Ohio State University,
Columbus, OH
Poster presentations will be on
display Monday, February 8 through Friday, February 12, 8:30 AM –
5:00 PM CST.
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V.
(“Kiadis”) is een biofarmaceutisch bedrijf in de
klinische fase dat innovatieve op NK-cellen gebaseerde
geneesmiddelen ontwikkelt voor de behandeling van levensbedreigende
ziekten, maakt bekend dat vier abstracts met betrekking tot het
K-NK-celtherapieplatform werden geaccepteerd voor presentatie op de
TCT Meetings, de Transplantation & Cellular Therapy Meetings
van de American Society of Transplantation and Cellular Therapy
(ASTCT) en het Center for International Blood & Marrow
Transplant Research (CIBMTR), die virtueel wordt gehouden van 8 tot
12 februari 2021.21
De abstracts zijn beschikbaar op 2021 TCT |
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
(confex.com)
De details van de mondelinge presentaties
zijn:
- Orale presentatie # 80: resultaten van een
fase I-onderzoek met Mb-IL21 ex vivo geëxpandeerde NK-cellen
(FC21-NK) voor patiënten met refractaire acute myeloïde
leukemiePresentator: Stefan O. Ciurea,
MDPresentatiedatum: woensdag 10 februari 2021:
16:45 - 17:00 uur CST
Details van de poster-presentaties zijn:
- Poster #172: Een fase I-onderzoek naar het
opnemen van Natural Killer-cellen (K-NK) voor patiënten met
chronische myeloïde leukemie (CML) en moleculaire restziekte na
therapie met tyrosinekinaseremmers
(TKI)Presentator: Lindsay Rein,
MDVerbonden aan: Duke University Medical Center,
Durham, NC
- Poster #411: Een fase I klinische studie naar
de veiligheid van IL-21-uitgebreide, kant-en-klare, natuurlijke
killercellen voor recidiverende/refractaire acute myeloïde leukemie
en myelodysplastisch syndroomPresentator:
Sumithira Vasu, MDVerbonden aan: The Ohio State
University, Columbus, OH
- Poster #531 – BMT CTN 1803: Haploidentical
Natural Killer Cells (K-NK002) om terugval na transplantatie bij
AML en MDS te voorkomen (NK-REALM)Presentator:
Sumithira VasuVerbonden aan: The Ohio State
University, Columbus, OH
Posterpresentaties
zijn te zien van maandag 8 februari tot en met vrijdag 12 februari,
8.30 - 17.00 uur CST.
Dit persbericht vormt een samenvatting
van het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
leidend.
Contacts
Kiadis: Maryann
Cimino, Director, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative cell-based medicines for
patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis' or, as appropriate, Kiadis'
officers' current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.